NKT A/S/ DK0010287663 /
2024-09-16 3:24:49 PM | Chg. - | Volume | Bid2024-08-12 | Ask2024-07-19 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
632.50DKK | - | 144 Turnover: 91,080 |
-Bid Size: - | -Ask Size: - | 33.19 bill.DKK | - | - |
GlobeNewswire
08-14
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
07-17
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allo...
GlobeNewswire
07-11
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
07-02
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the America...
GlobeNewswire
06-27
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
GlobeNewswire
05-22
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positi...
GlobeNewswire
05-21
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for t...
GlobeNewswire
05-20
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important...
GlobeNewswire
05-14
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GlobeNewswire
05-13
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Newsfile Corp
05-02
PlasCred Circular Innovations Inc. kündigt strategische Vereinbarung über Wachstumskapital mit Nimbu...
GlobeNewswire
04-29
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmu...
GlobeNewswire
04-25
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar